Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: BBI-608 (aka napabucasin) is an orally-administered first-in-class cancer stemness inhibitor. By targeting Stat3, BBI-608 blocks cancer stem cell (CSC) self-renewal and survival through suppressing stemness pathways as well as immune evasion. Potent anti-CSC and anti-metastatic activity was observed in preclinical models, with strong synergy between BBI-608 and 5-FU or irinotecan.
Background: Inhibition of mTOR in addition to EGFR may overcome upstream resistance to EGFR inhibitors in CRC. This phase II study evaluated the efficacy and safety of the combination of irinotecan, panitumumab and everolimus based on dosing established in the previously reported phase Ib study (Townsend JCO 2013 (suppl;abstr 14506)).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
